|
|
|
Dr Martin J Stoermer
Institute for Molecular Bioscience
University of Queensland
Brisbane, Qld 4072
Email: m.stoermer@imb.uq.edu.au
Tel: +61-7-3346-2991
Fax: +61-7-3346-2101 or 2103
Homepage: http://www.uq.edu.au/~uqmstoer/
| Research |
Current research is focused on the development of inhibitors for the NS3 protease of the Dengue and West Nile flavivirii using both classical structure and substrate-based drug design approaches as well as hybrid "rational" approaches.
We are also actively involved in the development of agonists and antagonists of the Protease Activated Receptor (PAR) family of G-Protein Coupled Receptors. In this program we are extensively applying high-field NMR spectroscopy to the elucidation of solution structure/conformation of small peptides and peptido-organic hybrids |
|
| Collaborations |
Prof. David Fairlie, IMB, University of Queensland
Dr. Paul Young, University of Queensland |
|
| Publications |
"Structure of West Nile Virus NS3 Protease: Ligand Stabilization of Catalytic Conformation." Gautier Robin, Keith Chappell, Martin J. Stoermer, Shu-Hong Hu, Paul R. Young, David P. Fairlie, Jennifer L Martin J. Mol. Biol. 2009, 385(5), 1568-1577.
"West Nile Virus NS2B/NS3 Protease as an Antiviral Target." Keith J. Chappell, Martin J. Stoermer, David P. Fairlie, and Paul R. Young Curr. Med. Chem. , 2008, 15(27), 2771-2784
"Potent Cationic Inhibitors of West Nile Virus NS2B/NS3 Protease With Serum Stability, Cell Permeability and Antiviral Activity." Martin J. Stoermer, Keith J. Chappell, Susann Liebscher, Christina M. Jensen, Chun H. Gan, Praveer K. Gupta, Wei-Jun Xu, Paul R. Young, and David P. Fairlie, J. Med. Chem. 2008, 51(18), 5714-5721.
"Mutagenesis of the West Nile virus NS2B cofactor domain reveals two regions essential for protease activity" Keith J. Chappell, Martin J. Stoermer, David P. Fairlie, and Paul R. Young J. Gen. Virol. , 2008, 89 (4), 1010-1014
"Generation and characterization of proteolytically active and highly stable truncated and full-length recombinant west nile virus NS3." Keith J. Chappell, Martin J. Stoermer, David P. Fairlie, and Paul R. Young Protein Expr. Purif. , 2007, 3(1), 87-96
"Insights to Substrate Binding and Processing by West Nile Virus NS3 Protease through Combined Modeling, Protease Mutagenesis, and Kinetic Studies." Keith J. Chappell, Martin J. Stoermer, David P. Fairlie, and Paul R. Young J. Biol. Chem., 2006, 281(50), 38448-38458.
"Potencies of Human Immunodeficiency Virus Protease Inhibitors In Vitro against Plasmodium falciparum and In Vivo against Murine Malaria" Katherine T. Andrews, David P. Fairlie, Praveen K. Madala, John Ray, David M. Wyatt, Petrina M. Hilton, Lewis A. Melville, Lynette Beattie, Donald L. Gardiner, Robert C. Reid, Martin J. Stoermer, Tina Skinner-Adams, Colin Berry, and James S. McCarthy, Antimicrobial Agents And Chemotherapy, 2006, 50(2) 639-648.
"West Nile virus NS3 protease: Site-directed mutagenesis and kinetic studies that identify key enzyme-substrate interactions " Keith J. Chappell, Tessa A. Nall, Martin J. Stoermer, Ning-Xia Fang, Joel D. A. Tyndall, David P. Fairlie, and Paul R. Young J. Biol. Chem., 2005, 280(4), 2896-2903
"Enzymatic characterisation and homology model of a catalytically active recombinant West Nile virus NS3 protease" T. A. Nall, K. J. Chappell, M. J. Stoermer, N. X. Fang, J. D. Tyndall, P. R. Young, and D. P. Fairlie, J. Biol. Chem., 2004, 279(47), 48535-48542.
Leung, D.; Schroder, K.; White, H.; Fang, N .-X.; Stoermer, M. J.; Abbenante, G.; Martin, J. L.; Young, P.; Fairlie, D. P. "Activity Of Recombinant Dengue 2 Virus NS3 Protease In The Presence Of NS2B Cofactor, Small Peptide Substrates, And Inhibitors", J. Biol. Chem. 2001, 276, 45762-45771.
Abbenante, G., Bergman, D.A., Brinkworth, R.I., March, D.A., Reid, R.C., Hunt, P., James, I.W., Dancer, R.J., Garnham, B., Stoermer M.J., and Fairlie, D.P. "Structure-Activity Relationships for Macrocyclic Peptido-Mimetic Inhibitors of HIV-1 Protease." Biorg. Med. Chem. Letters., 1996, 6, 2531.
Brinkworth, R.I., Stoermer, M.J., and Fairlie, D.P. "Flavones are inhibitors of HIV-1 Proteinase" Biochem. Biophys. Res. Communications, 1992, 188(2), 631 |
|
|
|
|
|
|
|
|
